Liver and Kidney Function Analysis in Hepatitis-B Patients Attending a Health Facility in Ikeja, Lagos, Nigeria

Liver and Kidney Function Analysis in Hepatitis-B Patients Attending a Health Facility in Ikeja, Lagos, Nigeria

Loading document ...
Loading page ...


Author(s): Olu Israel OYEWOLE, Mary Omolayo FAKOKUNDE

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.1244 146 575 65-68 Volume 6 - Apr 2017


Objective: The study was designed to determine changes in liver and kidney function parameters associated with hepatitis B infection among patients attending Nigerian Air Force Hospital (NAFH) Ikeja, Lagos, Nigeria. Methodology: The study made use of forty subjects (aged 35-50) divided into four groups of ten each (A-male non-hepatitis, B-female non-hepatitis, C-male hepatitis, D-female hepatitis). Serum samples were collected from the hepatitis patients and analyzed for some liver and kidney function parameters in comparism with their non-hepatitis counterparts. Results: There was significant increase in activities of serum enzymes -Alkaline phosphatase (ALP), Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) in male and female hepatitis patients compared with their non-hepatitis counterpart. Serum level of total protein was significantly reduced while total bilirubin was significantly elevated in hepatitis patients compared with the control. Measurement of kidney function biomarkers in the serum of hepatitis B infected patients showed elevated concentrations of urea, creatinine and uric acid while serum electrolytes (Na+, K+ and Cl-) were significantly reduced compared with the control. Conclusion: This results indicate that hepatitis B virus infection caused significant disruption of metabolic functions in the liver and kidney of the patients. This research is a further confirmation that other organ such as the kidney are negatively affected in hepatitis infection aside from the liver which is the principal target.


Hepatitis B, liver function, kidney function, aminotransferases, electrolytes


  1. Orth S.R. and Ritz E. (1998). The Nephritic Syndrome. N. Engl. J. Med. 338: 1202-1211.
  2. Macfarlane I., Bomford A. and Sherwood R.A. (2000). Liver Diseases and Laboratory Medicine. ACB Ventures Publications London. Pp. 67-72.
  3. Custer B., Sullivan S.D., Hazlet T.K., Iloeje U., Veenstra D.L. and Kowdley K. (2004). Global epidemiology of hepatitis B virus. Journal of ClinicalGastroenterology 38. (Suppl. 3): S158–168.
  4. Dienstag J.L. (2008). Hepatitis B Virus Infection. New England Journal of Medicine 359 (14): 1486–1500.
  5. Lok A.S. and McMahon B.J. (2007). Chronic hepatitis B. Hepatology. 45 (2): 507–539.
  6. Liaw Y.F., Brunetto M.R. and Hadziyannis S. (2010). The natural history of chronic HBV infection and geographical differences. Antiviral Therapy. 15: 25–33.
  7. Degertekin B. and Lok A.S. (2009). Indications for therapy in hepatitis B. Hepatology. 49:129–137.
  8. Cameron J.S. and Greger R. (1998). Renal function and testing of function. Oxford
  9. Textbook of Clinical Nephrology. Davison A.M., Cameron J.S., Grunfeld J.P., Kerr D.N.S., Rits E.and Winearl G.C. Eds. Pp: 36-39.
  10. Alberti A. and Caporaso N. (2011). HBV therapy: Guidelines and open issues. Digestive and Liver Disease: 43 (Suppl 1): S57–63.
  11. Lefevre M.L. (2014). Screening for Hepatitis B virus infection in non-pregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 161 (1): 58–66.
  12. Gilbert R.D. and Wiggelinkhuizen J. (1994). The clinical course of hepatitis B virus-associated nephropathy. Pead. Nephrol. 8:11–14.
  13. Levy M. and Chen N. (1991). Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int. Suppl 35: S24–S33.
  14. Schmidt E. and Schmidt F.W. (1979). Enzyme diagnosis in diseases of the liver and biliary system. Adv. Clin. Enzymol. 1: 239-242.
  15. Shahjahan M., Sabitha K.E., Jainu M. and Shyamala-Devi C.S. (2004). Effect of Solanum trilobatum against carbon tetrachloride-induced hepatic damage in albino rats. Indian J. Med. Res. 120: 194-198.
  16. Ghouri N., Preiss D. and Sattar N. (2010). Liver enzymes, nonalcoholic fatty liver disease and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology 52 (3): 1156–1161.
  17. Giboney P.T. (2005). Mildly elevated liver transaminase levels in the asymptomatic patient, American Family Physician. 71 (6): 1105-1110.
  18. Cotran R.S., Kumar V., Fausto N., Nelso F., Robbins S.L. and Abdul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, MO: Elsevier Saunders. p. 878.
  19. Akanji M.A., Olagoke O.A. and Oloyede O.B. (1993). Effect of chronic consumption of metabisulphite on the integrity of the kidney cellular system. Toxicol. 81: 173-179.
  20. Berg J.M. Tymoczko, J.L and Stryer L. (2006). Biochemistry. W.H. Freeman. pp. 656–660.
  21. Nalpas B., Vassault A., Charpin S., Lacour B. and Berthelot P. (1986). Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology. 6 (4): 608–614.
  22. Tredger J.M. and Sherwood K.A. (1997). The liver: New functional, prognostic and diagnostic tests. Annals of Clinical Biochemistry. 34: 121-141.
  23. Renner E.L. (1995). Liver function test. Ballieres Clinical Gastroenterology. 9: 661-772.
  24. Kao T.W., Chou C.H., Wang C.C., Chou C.C., Hu J. and Chen W.L. (2012). Associations between serum total bilirubin levels and functional dependence in the elderly. Internal Medicine Journal. 42 (11): 1199–1207.
  25. Sedlak T.W., Saleh M., Higginson D.S., Paul B.D., Juluri K.R. and Snyder S.H. (2009). Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proceedings of the National Academy of Sciences. 106 (13): 5171–5176.
  26. Shirley D.G., Walter S.J. and Noormohamed F.H. (2002). Natriuretic effect of caffeine: assessment of segmental sodium reabsorption in humans. Clinical Science. 103 (5): 461–466.
  27. Connor F.L., Rosenberg A.R., Kennedy S.E., Bohane T.D. (2003). HBV associated nephrotic syndrome: Resolution with oral lamivudine. Arch Dis Child. 88:446–449.
  28. Filler G., Feber J., Weiler G. and Saux N. (2003). Another case of HBV associated membranous glomerulonephritis resolving on lamivudine. Arch. Dis. Child. 88:460.

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue June 2023

Volume 12, June 2023

Table of Contents

World-wide Delivery is FREE

Share this Issue with Friends:

Submit your Paper